Results 61 to 70 of about 728 (161)

Differentiating cardiac troponin levels during cardiac myosin inhibition or cardiac myosin activation treatments: drug effect or the canary in the coal mine? [PDF]

, 2023
Purpose of Review: Cardiac myosin inhibitors (CMIs) and activators are emerging therapies for hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection fraction (HFrEF), respectively.
Lee, Matthew M. Y., Masri, Ahmad
core   +1 more source

Evaluation of Percutaneous Intramyocardial Septal Pulsed Field Ablation in a Rabbit Model: Safety, Efficacy, and Feasibility

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao, Hua-lei Dai, Si-ming Tao, Yi-jian Zhang, Ji Jia, Li-juan Song, Man Yang, Yun-na Ge, Xi-ya Wang, Juan Qing, Piotr Musialek   +10 more
wiley   +1 more source

What's new in heart failure? October 2024 [PDF]

No abstract ...
Aimo, Alberto, Codina, Pau, Lee, Matthew M. Y., Tomasoni, Daniela   +3 more
core   +4 more sources

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants

JACC: Basic to Translational Science, 2022
This phase 1, randomized, double-blind, placebo-controlled study of aficamten (formerly CK-3773274) in healthy adults identified a pharmacologically active range of doses and exposures. At doses that were pharmacologically active (single doses of ≤50 mg or daily dosing of ≤10 mg for 14 or 17 days), aficamten appeared to be safe and well tolerated ...
Malik, Fady I., Robertson, Laura A., Armas, Danielle R., Robbie, Edward P., Osmukhina, Anna, Xu, Donghong, Li, Hanbin, Solomon, Scott D.   +7 more
openaire   +2 more sources

Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options

Molecular Genetics &Genomic Medicine, Volume 13, Issue 7, July 2025.
Pediatric cardiomyopathies are rare, heterogeneous, and challenging conditions, often with a genetic etiology. We estimated the yield of genetic testing in a pediatric cohort with cardiomyopathies and evaluated the potential candidacy to current or emerging treatments based on genetic results. Over one‐third had a conclusive genetic test, including 25%
Adelaide Ballerini, Francesca Girolami, Alessia Gozzini, Silvia Passantino, Mattia Zampieri, Alberto Marchi, Alessia Tomberli, Giovanni B. Calabri, Gaia Spaziani, Giulio Porcedda, Elena Bennati, Silvia Favilli, Iacopo Olivotto   +12 more
wiley   +1 more source

Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease: From Molecular Pathophysiology to Personalized Medicine [PDF]

, 2023
Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left ventricular wall thickness not solely explained by abnormal loading conditions.
Altobelli, Ippolita, Bakalakos, Athanasios, De Michele, Gianantonio, Diana, Gaetano, Elliott, Perry M, Falco, Luigi, Limongelli, Giuseppe, Lioncino, Michele, Monda, Emanuele, Palmiero, Giuseppe, Perna, Alessia, Rubino, Marta, Verrillo, Federica   +12 more
core  

Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]

Zhongguo quanke yixue
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj   +1 more source

Efficacy and Safety of Percutaneous Transluminal Septal Myocardial Ablation Treating Hypertrophic Cardiomyopathy: Systematic Review and Meta‐Analysis

International Journal of Clinical Practice, Volume 2025, Issue 1, 2025.
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). Objective: To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.
Sun Qinyu, Deng Yifan, Yu Jiling, Zhang Zhaoyuan, Cao Gan, Yang Tianxiao, Fang Zhen, Ji Jun, He Shenghu, Zhang Jing, Luigi Sciarra   +10 more
wiley   +1 more source

Cardiomyopathy: pathogenesis and therapeutic interventions

MedComm, Volume 5, Issue 11, November 2024.
Cardiomyopathy is a group of diseases characterized by structural and functional damage to the myocardium. Many specific gene mutations, environmental factors, and metabolic disorders may cause cardiomyopathy. Traditional therapeutic includes drug and surgery. With the growing comprehension of the molecular mechanisms underlying cardiomyopathy.
Shitong Huang, Jiaxin Li, Qiuying Li, Qiuyu Wang, Xianwu Zhou, Jimei Chen, Xuanhui Chen, Abdelouahab Bellou, Jian Zhuang, Liming Lei   +9 more
wiley   +1 more source

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

Reviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani   +7 more
doaj   +1 more source